Clinical trials in Krefeld

47 clinical trials in Krefeld, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Krefeld at a glance

clinical trials

Research sites0

Quick filters

47 trials in Krefeld

Open in trial search

Non-small cell lung cancer+1

Recruiting

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Sargramostim
Sponsor:Greenwich LifeSciences Inc.

Contact Research Centre

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Vulval cancer

Recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy

Registered drugNo placebo

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lenvatinib
Sponsor:AGO Research GmbH

Contact Research Centre

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AGO Research GmbH

Contact Research Centre

Chronic lymphocytic leukaemia

Recruiting

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:University Of Cologne

Contact Research Centre

Medulloblastoma

Recruiting

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:University Medical Center Hamburg-Eppendorf

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Adagrasib
Sponsor:Mirati Therapeutics Inc.

Contact Research Centre

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Carboplatin
Sponsor:The University Of Birmingham

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Krefeld

What the registry says about research in the country

01 Pediatric Oncology Research

Groundbreaking trials focusing on treating lymphoblastic lymphoma and medulloblastoma in children and young adults, with innovative therapeutic approaches combining surgery, radiation, and chemotherapy protocols.

B-cell lymphoma treatments
High-risk medulloblastoma therapy
Ependymoma management

Advanced protocols incorporating targeted therapies and personalized treatment approaches for young patients.

02 Breast Cancer Innovation

Multiple studies investigating novel treatments for hormone receptor-positive breast cancer, including combinations of immunotherapy and targeted therapies.

Triple-negative breast cancer treatment
Endocrine therapy optimization
Metastatic disease management

Focus on improving survival outcomes through personalized therapeutic approaches.

03 Gynecologic Oncology

Comprehensive research into treatments for ovarian cancer, cervical cancer, and other gynecologic malignancies, testing new drug combinations and immunotherapy approaches.

Advanced ovarian cancer therapies
Targeted treatments for cervical cancer
Recurrent disease management

Innovative protocols combining standard treatments with novel therapeutic agents.

Back to Germany All countries